Pfizer is "very close" to applying for an emergency use approval for its Covid-19 vaccine after collecting safety data to submit to US regulators, the company's CEO said on Tuesday, according to a report. Last week, Pfizer and its partner BioNTech SE reported that an interim analysis showed their experimental vaccine was more than 90% effective in preventing symptomatic cases of Covid-19. "We are very close to submitting for an emergency use authorization," Albert Bourla told medical news site Stat. On Tuesday, Pfizer CEO said that a key safety milestone had been reached in the study of its Covid-19 vaccine. In India, there are five COVID-19 vaccine candidates under various stages of clinical trials in India of which two are in the third phase.

Source: Mint November 18, 2020 03:00 UTC